Repaglinide And Glp-1 On Insulin Sensitivity

lthough GLP-1 receptor agonists improve insulin sensitivity secondary to weight loss, the only true direct insulin-sensitising drugs are thiazolidinediones. Because of side-effects associated with type 2 diabetes therapy, these drugs have not gained widespread use.

In the presence of glucagon-like peptide-1 (GLP-1), insulin secretion by repaglinide was augmented significantly but to lesser extent and showed different dynamics from that by glimepiride.

It discusses the evidence supporting the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) as potential adjunctive therapy in T1D to reduce weight and improve insulin resistance.

Furthermore, visual representations like the one above help us fully grasp the concept of Repaglinide And Glp-1 On Insulin Sensitivity.

When GIP was combined with synthetic GLP-1 receptor agonists, additive effects on both glucose levels and body weight occurred. GIP was also found to have very modest insulin-sensitizing...

These authors performed a retrospective investigation of long-acting GLP-1RA and SGLT-2i as adjuncts to insulin in adults with T1D on multiple insulin injections or insulin pumps, in a real-world clinical setting.

GLP1 RAs have an established efficacy and safety profile. Their benefits derive from their blood glucoselowering effects, which include pancreatic betacellmediated glucosedependent insulin secretion and suppressed glucagon release, and their ability to slow gastric emptying and promote satiety.